Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The poliovirus type 2 capsid protein from the Sabin strain forms part of an attenuated virus used globally as an oral polio vaccine component. Its structure provides both immunogenicity—eliciting strong protective antibody responses—and safety through engineered genetic changes that reduce its ability to cause disease. However, under certain conditions such as low vaccination coverage or prolonged circulation/recombination events within populations or individuals with immune deficiencies, these viruses can mutate back toward more virulent forms capable of causing disease outbreaks similar to wild-type virus infections.
N/A
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poliovirus Type 2 Capsid Protein (Sabin Strain) (N/A).